Circulating biomarkers of cognitive decline and dementia - PubMed (original) (raw)
Review
. 2006 Feb;364(1-2):91-112.
doi: 10.1016/j.cca.2005.06.015. Epub 2005 Sep 1.
Affiliations
- PMID: 16139826
- DOI: 10.1016/j.cca.2005.06.015
Review
Circulating biomarkers of cognitive decline and dementia
Vincenzo Solfrizzi et al. Clin Chim Acta. 2006 Feb.
Abstract
Plasma and serum biochemical markers proposed for cognitive decline of degenerative (Alzheimer's disease, AD) or vascular origin and predementia syndromes (mild cognitive impairment and other related entities) are based on pathophysiologic processes such as lipoprotein metabolism (total cholesterol, apolipoprotein E, 24S-hydroxy-cholesterol), and vascular disease (homocysteine, lipoprotein(a)); SP formation (amyloid beta(Abeta)-protein, Abeta autoantibodies, platelet APP isoforms), oxidative stress (isoprostanes, vitamin E), and inflammation (cytokines). This review will focus on the current knowledge on circulating serum and plasma biomarkers of cognitive decline and dementia that are linked to cholesterol homeostasis and lipoprotein abnormalities, senile plaque formation and amyloid precursor protein (APP) metabolism, oxidative stress, and inflammatory reactions. Special emphasis will, however, be placed on biomarkers related to lipoprotein metabolism and vascular disease. Analytically, most plasma and serum proteins or metabolites lack reproducibility, sensitivity, or specificity for the diagnosis, risk and progression assessment, or therapeutic monitoring of AD and other dementing disorders. Measures linked to lipoprotein metabolism and vascular disease, APP metabolism, oxidative stress, or inflammation appear altered in AD relative to controls, but lack sufficient discriminatory power. Measures combining several biomarkers or incorporating a range of proteins in plasma and small molecule metabolites are promising approaches for the development of plasma or serum-based diagnostic tests for AD and other dementing disorders, as well as for predementia syndromes.
Similar articles
- Lipid metabolism in cognitive decline and dementia.
Panza F, D'Introno A, Colacicco AM, Capurso C, Pichichero G, Capurso SA, Capurso A, Solfrizzi V. Panza F, et al. Brain Res Rev. 2006 Aug;51(2):275-92. doi: 10.1016/j.brainresrev.2005.11.007. Epub 2006 Jan 10. Brain Res Rev. 2006. PMID: 16410024 Review. - Plasma biomarkers for mild cognitive impairment and Alzheimer's disease.
Song F, Poljak A, Smythe GA, Sachdev P. Song F, et al. Brain Res Rev. 2009 Oct;61(2):69-80. doi: 10.1016/j.brainresrev.2009.05.003. Epub 2009 May 21. Brain Res Rev. 2009. PMID: 19464319 Review. - Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG. Graff-Radford NR, et al. Arch Neurol. 2007 Mar;64(3):354-62. doi: 10.1001/archneur.64.3.354. Arch Neurol. 2007. PMID: 17353377 - Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Fagan AM, et al. Arch Neurol. 2007 Mar;64(3):343-9. doi: 10.1001/archneur.64.3.noc60123. Epub 2007 Jan 8. Arch Neurol. 2007. PMID: 17210801 - Plasma lipoprotein beta-amyloid in subjects with Alzheimer's disease or mild cognitive impairment.
Mamo JC, Jian L, James AP, Flicker L, Esselmann H, Wiltfang J. Mamo JC, et al. Ann Clin Biochem. 2008 Jul;45(Pt 4):395-403. doi: 10.1258/acb.2008.007214. Ann Clin Biochem. 2008. PMID: 18583625
Cited by
- Identification and Analysis of BCAS4/hsa-miR-185-5p/SHISA7 Competing Endogenous RNA Axis in Late-Onset Alzheimer's Disease Using Bioinformatic and Experimental Approaches.
Sabaie H, Talebi M, Gharesouarn J, Asadi MR, Jalaiei A, Arsang-Jang S, Hussen BM, Taheri M, Jalili Khoshnoud R, Rezazadeh M. Sabaie H, et al. Front Aging Neurosci. 2022 Feb 21;14:812169. doi: 10.3389/fnagi.2022.812169. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35264942 Free PMC article. - The relationship between plasma amyloid-β peptides and the medial temporal lobe in the homebound elderly.
Sun X, Bhadelia R, Liebson E, Bergethon P, Folstein M, Zhu JJ, Mwamburi DM, Patz S, Qiu WQ. Sun X, et al. Int J Geriatr Psychiatry. 2011 Jun;26(6):593-601. doi: 10.1002/gps.2568. Epub 2010 Dec 9. Int J Geriatr Psychiatry. 2011. PMID: 21480376 Free PMC article. - Serum lipids are related to Alzheimer's pathology in nursing home residents.
Lesser GT, Haroutunian V, Purohit DP, Schnaider Beeri M, Schmeidler J, Honkanen L, Neufeld R, Libow LS. Lesser GT, et al. Dement Geriatr Cogn Disord. 2009;27(1):42-9. doi: 10.1159/000189268. Epub 2009 Jan 8. Dement Geriatr Cogn Disord. 2009. PMID: 19129700 Free PMC article. - Hypercholesterolemia and the Increased Risk of Vascular Dementia: a Cholesterol Perspective.
Shang G, Shao Q, Lv K, Xu W, Ji J, Fan S, Kang X, Cheng F, Wang X, Wang Q. Shang G, et al. Curr Atheroscler Rep. 2024 Aug;26(8):435-449. doi: 10.1007/s11883-024-01217-3. Epub 2024 May 30. Curr Atheroscler Rep. 2024. PMID: 38814418 Review. - Cognitive dysfunction associated with COVID-19: Prognostic role of circulating biomarkers and microRNAs.
Alvarez M, Trent E, Goncalves BS, Pereira DG, Puri R, Frazier NA, Sodhi K, Pillai SS. Alvarez M, et al. Front Aging Neurosci. 2022 Oct 4;14:1020092. doi: 10.3389/fnagi.2022.1020092. eCollection 2022. Front Aging Neurosci. 2022. PMID: 36268187 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical